VivoSeq
Other

BRAF V600 Mutation

0

Pipeline Programs↗

2

Active Trials↗

4

Companies Involved↗

BRAF V600 Mutation is an early-stage landscape with 0 programs across 4 companies. The most active players are Roche, Haisco Pharmaceutical Group Co., Ltd., GSK.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

75/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

0 programs

PreclinicalHaisco Pharmaceutical Group Co., Ltd. logo

Haisco Pharmaceutical Group Co., Ltd.

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalS

Shanghai Kechow Pharma, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

7

clinical trials

Completed3 · 43%
Recruiting1 · 14%
Withdrawn1 · 14%
Unknown status1 · 14%
Not yet recruiting1 · 14%

Clinical Trials

Trial Activity

7 trials

Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation
Recruiting·Haisco Pharmaceutical Group Co., Ltd. logoHaisco Pharmaceutical Group Co., Ltd.·Phase 1·NCT06536400·316 enrolled
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
Not yet recruiting·CCancer Research UK·Phase 2/3·NCT07440290·30 enrolled
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
Completed·Roche logoRoche·Phase 2·NCT01524978·208 enrolled
An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol
Completed·Roche logoRoche·Phase 4·NCT01739764·215 enrolled
A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors
Completed·GSK logoGSK·Phase 1·NCT01954043·23 enrolled
Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations
Withdrawn·National Cancer Institute (NCI)·Phase 2·NCT03794297
A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation
Unknown status·SShanghai Kechow Pharma, Inc.·Phase 1·NCT03781219·45 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)